Preclinical development of a novel class of cxcr4 antagonist impairing solid tumors growth and metastases

HIGHLIGHTS

• who: Antagonist Impairing Solid Tumors et al. from the IBB-CNR, CNR, Naples, Italy have published the article: Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases, in the Journal: PLOS ONE | www.plosone.org of September/13,/2013
• what: To evaluate the specific peptide binding to CXCR4, the experiments were also conducted in MCF-7 cell line, CXCR7 overexpressing cells using anti-CXCR7 antibody (R and amp;D FAB4227A clone 11G8) and in COLO205, human colon cancer cells, CXCR3 overexpressing cells, using anti-CXCR3 antibody (BD Pharmingen 560831 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.